MedPath

Etude des effets d’un antagoniste non spécifique de l’endothéline (le bosentan) sur l’activité orthosympathique et le chémoréflexe.

Conditions
healthy subjectsobstructive sleep apnea(Bosentan is used in clinic in pulmonary hypertension)
Registration Number
EUCTR2006-003133-33-BE
Lead Sponsor
Hôpital Erasme
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Authorised-recruitment may be ongoing or finished
Sex
Male
Target Recruitment
Not specified
Inclusion Criteria

healthy male subjects: aged between 18 and 65 years, no medication

male patients with obstructive sleep apnea (hypopnea/apnea index > 30) aged between 18 and 65 years

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

diabetes
alcohol abuse
cyclosporin use
glyburide use
hepatic disease
women
age

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: show if endothelin plays an important role in the control of ventilation in healthy subjects and obstructive sleep apnea patients.;Secondary Objective: better understanding of chemoreflex;Primary end point(s): dicrease in peripheric chemoreflex sensibility
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath